# Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

> **NCT00511459** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 228 (actual)

## Conditions studied

- Locally Recurrent and Metastatic Breast Cancer

## Interventions

- **DRUG:** AMG 386 Placebo
- **DRUG:** AMG 386
- **DRUG:** Bevacizumab
- **DRUG:** AMG 386
- **DRUG:** AMG 386
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00511459
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2010-08
- **Final completion:** 2014-05
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2015-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00511459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00511459, "Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00511459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*